Surgically implantable long-term antipsychotic delivery systems for the treatment of schizophrenia

  • Siegel S
  • Winey K
  • Gur R
 et al. 
  • 19


    Mendeley users who have this article in their library.
  • 36


    Citations of this article.


Non-adherence with medication remains a major correctable cause for poor outcome in schizophrenia. We describe a surgically implantable preparation of haloperidol with the aim that patients will have superior outcomes with improved medication adherence from implants. In contrast to depot formulations, implantable pellets could last many months, providing symptomatic improvement for periods of time never before possible. Additionally, in the event of unacceptable side effects, implants could be removed, offering a degree of reversibility not available with depot formulations. A surgically-implantable formulation of haloperidol has been created using biodegradable polymers. Implants have been characterized for in-vitro kinetics, as well as in-vivo bioactivity in rodents. Haloperidol implants demonstrate steady release of drug for 5 months. Animals treated with haloperidol implants display increased striatal D2 receptor expression as well as increased apomorphine stimulated locomotion. Surgically-implantable formulations are a viable approach to provide long-term delivery of antipsychotic medications to patients with psychotic disorders. © 2002 American College of Neuropsychopharmacology. Published by Elsevier Science Inc.

Author-supplied keywords

  • Adherence
  • Antipsychotic
  • Compliance
  • Implant
  • Schizophrenia
  • Treatment

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Steven J. Siegel

  • Raquel E. Gur

  • Robert H. Lenox

  • Warren B. Bilker

  • Debbie Ikeda

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free